How Tumorigenesis And Drug Design Are Affected By Mutant P53 Stability

In the May 15th issue of G&D, Dr. Guillermina Lozano (MD Anderson Cancer Center) and colleagues reveal how the stabilization of a mutated form of p53 affects oncogenesis, and lends startling new insight into the potential pitfalls of using Mdm2 inhibitors for cancer therapy.”Our data are both exciting and sobering: we must classify tumors with respect to p53 mutation status prior to treatment,” emphasizes Dr. Lozano.

More: continued here

Filed under: Cancer on May 17th, 2008